Eldelumab (Anti-CXCL10 / IP-10)

Synonyms: BMS-936557; MDX-1100

Catalog No.A2525 Purity:99%

Eldelumab (Anti-CXCL10 / IP-10) is a humanised monoclonal antibody (IgG1 type) targeting CXCL10. Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease. MW: 145.5 KD.

Purity & Quality Control

Batch: A252501 Purity: 99% Protein concentration: 6.43mg/ml Endotoxin Level: ＜1EU/mg

Choose Selective CXCR Inhibitors

Name	Citation	CXCR1	CXCR2	CXCR4	CXCR3	Others
WZ811	20			++++
Mavorixafor	0			+
AMG 487	1				+++
Motixafortide (BL-8040)	0			++++		cyclin-D1,MCL-1,Bcl-2
Navarixin (SCH-527123)	4	++	+++
MSX-122	1			+++
LY2510924	2			++++
Reparixin (Repertaxin)	17	++++	+			CXCL8
SB225002	76		++
SB 265610		✔
Balixafortide (POL6326)			✔
SX-682	✔
MSX-130			✔
MSX-127			✔
AZD5069		✔
Danirixin (GSK1325756)		✔			CXCL8
LIT-927			✔		CXCL12
AMD3465 hexahydrobromide			✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Eldelumab (Anti-CXCL10 / IP-10) is a humanised monoclonal antibody (IgG1 type) targeting CXCL10. Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease. MW: 145.5 KD.

Product Details

CAS No.	946414-98-8
Molecular Weight	145.5 kDa
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field